• United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised stock options for 9,500 shares at USD 146.03 on May 21, 2026.
• Rothblatt sold 9,500 shares in multiple transactions at prices ranging from USD 557.85 to USD 566.42.
• Directly held common stock ended the day at 40,513 shares, down from 50,013 shares immediately following the option exercise.
• Directly held stock options totaled 183,410 following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000059), on May 22, 2026, and is solely responsible for the information contained therein.